HCW boosts biotech practice with four additions

New York City-based investment bank H.C. Wainwright & Co. has expanded its biotechnology practice with four hires. The firm has named Dr. Swayampakula Ramakanth as managing director in equity research. Also, HCW has added Dr. Aileen M. Gibbons, Dr. Sean W. Hagerty and Dr. Jeffery R. Smith to the HCW healthcare investment banking team as vice presidents.


NEW YORK–(BUSINESS WIRE)–H.C. Wainwright & Co., LLC (“HCW”) announced today the addition of one Managing Director in Equity Research and three Vice Presidents in Investment Banking to further enhance its Biotechnology Practice.

Swayampakula Ramakanth (“RK”), PhD. joins HCW in Equity Research as Managing Director, Senior Biotechnology Analyst. Prior to joining HCW, Dr. Ramakanth was a Junior Analyst at Jefferies and Merrill Lynch covering large cap pharmaceuticals, and at First Albany and Rodman & Renshaw covering biotechnology companies. Dr. Ramakanth previously conducted bench research at Regeneron Pharmaceuticals, Inc. and directed a preclinical drug development group. Dr. Ramakanth’s expertise consists of companies in the oncology, infectious diseases, metabolic disorders and animal health sectors. Dr. Ramakanth has over 10 years of experience as a life sciences equity analyst and 7 years of biotechnology industry experience.

Aileen M. Gibbons, PhD., Sean W. Hagerty, PhD. and Jeffery R. Smith, PhD. join the HCW Healthcare Investment Banking team as Vice Presidents. Dr. Gibbons earned her doctorate in liposomal formulation of protease inhibitor proteins to treat inflammatory lung diseases from the Royal College of Surgeons in Ireland. Dr. Hagerty earned his doctorate in Cellular and Molecular Biology from NYU School of Medicine by characterizing the role of TORC1 in Schwann cell dedifferentiation. Dr. Smith earned his doctorate in Cancer Biology from the Gerstner Sloan-Kettering Graduate School of Biomedical Sciences investigating the role of Rho GTPases in cytoskeletal remodeling during breast cancer proliferation and metastasis.

“We are pleased that RK, Aileen, Sean and Jeff have decided to join HCW to further grow our biotechnology franchise,” commented Mark Viklund, Chief Executive Officer of HCW. “RK joins Ren Benjamin, PhD. and Andrew Fein in Biotechnology Equity Research to enhance HCW’s goal of providing insightful investment ideas to our institutional investor clientele. The addition of Aileen, Sean and Jeff to our investment banking practice will enable HCW to deliver differentiated capital markets advice to our biotechnology clients given their significant scientific achievements in their fields of study.”

About H.C. Wainwright & Co., LLC
H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. H.C. Wainwright was established in 1868 and is headquartered in New York City.